J&J’s COVID Vaccine Contract With US Bucks Trend Of Increasingly Lucrative Deals
Estimated $14 price per dose for Janssen’s investigational vaccine is first drop in value since Operation Warp Speed started signing contracts. The $1bn purchase order for 100 million doses and earlier $456m for development work is considerably less lucrative than the $2.1bn deal with GSK/Sanofi announced last week, especially since Janssen’s product may end up being a one-dose regimen.
The $1bn commitment from the US for 100 million doses of Johnson & Johnson’s coronavirus vaccine announced on 5 August is a hefty order – but only if you don’t compare it to the deal the government struck with GlaxoSmithKline plc and Sanofi the week before.
Under the agreement with the Janssen subsidiary, the US Health and Human Services Department and the Department of Defense will...